The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy.
Lin. Hong-Yuan HY
Key Findings
- COVID‑19 severe cases resemble sepsis in how the body reacts
- Immunomodulatory treatments used for sepsis could be considered for severe COVID‑19
- There is still no consensus or solid clinical guidelines for such therapies
Practical Outcomes
- For now, the idea that immune‑modulating drugs might aid severe COVID‑19 is interesting, but there’s no actionable guidance on using thymosin‑alpha‑1. Biohackers should wait for concrete trial data before adding it to their regimens.
Summary
The paper says severe COVID‑19 acts like sepsis and that drugs that modulate the immune system, which have been used for sepsis, might help, but it doesn’t give clear dosing or protocols for any specific peptide like thymosin‑alpha‑1.
Abstract
COVID-19 is known for its magical infectivity, fast transmission and high death toll based on the large number of infected people. From the perspective of the clinical manifestation, autopsy examination and pathophysiology, the essence of COVID-19 should be viewed as a sepsis induced by viral infection, and has the essential characteristics as sepsis induced by other pathogens. Therefore, in addition to etiological and supportive treatment, immunomodulatory therapy is also appropriate to severe COVID-19. Although there is still a lack of consensus on immunotherapy for sepsis so far, relatively rich experiences have been accumulated in the past decades, which will help us in the treatment of severe COVID-19. This article will elaborate immunotherapy of sepsis, though it may not be consistent.
Study Information
pubmed
2020
2020-06-15T00:00:00.000Z
10.1016/j.cjtee.2020.06.002
43
75